Michael J. Borowitz
About
Michael J. Borowitz is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Pathology and Forensic Medicine.
According to data from OpenAlex, Michael J. Borowitz has authored 332 papers receiving a total of 23.2k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Public Health, Environmental and Occupational Health, 143 papers in Hematology and 77 papers in Pathology and Forensic Medicine. Recurrent topics in Michael J. Borowitz's work include Acute Lymphoblastic Leukemia research (170 papers), Acute Myeloid Leukemia Research (86 papers) and Lymphoma Diagnosis and Treatment (74 papers). Michael J. Borowitz is often cited by papers focused on Acute Lymphoblastic Leukemia research (170 papers), Acute Myeloid Leukemia Research (86 papers) and Lymphoma Diagnosis and Treatment (74 papers). Michael J. Borowitz collaborates with scholars based in United States, Canada and Germany. Michael J. Borowitz's co-authors include James W. Vardiman, Daniel A. Arber, Clara D. Bloomfield, Michelle M. Le Beau, Robert P. Hasserjian, Jürgen Thiele, Mario Cazzola, Attilio Orazi, Meenakshi Devidas and Stephen P. Hunger and has published in prestigious journals such as New England Journal of Medicine, JAMA and The Journal of Experimental Medicine.
In The Last Decade
Michael J. Borowitz
325 papers receiving 22.6k citations
Hit Papers
Author Peers
Peers are selected by citation overlap in the author's most active subfields. citations · hero ref
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Michael J. Borowitz | 12.8k | 7.9k | 6.0k | 4.9k | 4.7k | 332 | 23.2k | |
| Mark R. Litzow | 11.9k 0.9× | 4.9k 0.6× | 4.9k 0.8× | 5.5k 1.1× | 4.8k 1.0× | 597 | 18.9k | |
| Ravi Bhatia | 8.9k 0.7× | 4.5k 0.6× | 4.4k 0.7× | 4.8k 1.0× | 5.9k 1.3× | 463 | 21.8k | |
| Hillard M. Lazarus | 13.4k 1.0× | 5.6k 0.7× | 5.9k 1.0× | 4.6k 0.9× | 7.0k 1.5× | 545 | 25.8k | |
| Elias Jabbour | 18.1k 1.4× | 7.6k 1.0× | 9.4k 1.6× | 6.9k 1.4× | 6.1k 1.3× | 1.2k | 25.4k | |
| Dietger Niederwieser | 18.3k 1.4× | 4.5k 0.6× | 7.5k 1.3× | 4.4k 0.9× | 5.4k 1.2× | 535 | 26.8k | |
| Farhad Ravandi | 24.8k 1.9× | 9.3k 1.2× | 10.4k 1.7× | 13.0k 2.7× | 7.5k 1.6× | 1.3k | 34.7k | |
| Aloïs Gratwohl | 17.1k 1.3× | 4.4k 0.6× | 4.8k 0.8× | 2.8k 0.6× | 4.7k 1.0× | 515 | 23.8k | |
| James W. Vardiman | 14.5k 1.1× | 4.0k 0.5× | 8.9k 1.5× | 6.8k 1.4× | 3.3k 0.7× | 118 | 22.3k | |
| Mary M. Horowitz | 20.8k 1.6× | 6.1k 0.8× | 4.9k 0.8× | 1.7k 0.4× | 7.8k 1.7× | 368 | 28.5k | |
| Charles A. Schiffer | 15.5k 1.2× | 4.5k 0.6× | 6.5k 1.1× | 6.8k 1.4× | 4.4k 0.9× | 280 | 22.0k |
Countries citing papers authored by Michael J. Borowitz
Since
Specialization
Citations
This map shows the geographic impact of Michael J. Borowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Borowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Borowitz more than expected).
Fields of papers citing papers by Michael J. Borowitz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael J. Borowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Borowitz. The network helps show where Michael J. Borowitz may publish in the future.
Co-authorship network of co-authors of Michael J. Borowitz
This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Borowitz. A scholar is included among the top collaborators of Michael J. Borowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Borowitz. Michael J. Borowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Groves, Christopher J., Michael A. Linden, Ahmad Al‐Attar, et al.. (2025). Ad hoc antibody modification of a validated flow cytometric immunophenotyping panel—recommendations and safeguards for clinical laboratories. Cytometry Part B Clinical Cytometry. 110(1). 11–21.
2.
Hogan, Laura, Patrick A. Brown, Lingyun Ji, et al.. (2023). Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. Journal of Clinical Oncology. 41(25). 4118–4129.
3.
Jain, Tania, W. Brian Dalton, Sergiu Paşca, et al.. (2023). Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia. Leukemia Research. 131. 107345–107345.
4.
Brown, Patrick A., Lingyun Ji, Xinxin Xu, et al.. (2021). A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. Blood. 138(Supplement 1). 363–363.
5.
Mattano, Leonard A., Meenakshi Devidas, Kelly W. Maloney, et al.. (2021). Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. Journal of Clinical Oncology. 39(14). 1540–1552.
6.
Burke, Michael J., Meenakshi Devidas, Zhiguo Chen, et al.. (2021). Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232. Leukemia. 36(3). 648–655.
7.
Wake, Laura, Derek B. Allison, Jody E. Hooper, et al.. (2021). Pathology Residency Program Special Expertise Tracks Meet the Needs of an Evolving Field. Academic Pathology. 8. 2466136426–2466136426.
8.
Angiolillo, Anne, Reuven J. Schore, John A. Kairalla, et al.. (2019). Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932. Blood. 134(Supplement_1). 824–824.
9.
Brown, Patrick A., Lingyun Ji, Xinxin Xu, et al.. (2019). A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. Blood. 134(Supplement_2). LBA–1.
10.
Karaba, Andrew H., Paul W. Blair, Kevin Martin, et al.. (2019). The Effects of a Systemwide Diagnostic Stewardship Change on West Nile Virus Disease Ordering Practices. Open Forum Infectious Diseases. 6(12). ofz488–ofz488.
11.
Wood, Brent L., David Wu, Beryl Crossley, et al.. (2017). Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 131(12). 1350–1359.
12.
Salzer, Wanda L., Michael J. Burke, Meenakshi Devidas, et al.. (2017). Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer. 124(6). 1150–1159.
13.
Larsen, Eric, Meenakshi Devidas, Si Chen, et al.. (2016). Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232. Journal of Clinical Oncology. 34(20). 2380–2388.
14.
Asselin, Barbara L., Meenakshi Devidas, Lu Chen, et al.. (2015). Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404. Journal of Clinical Oncology. 34(8). 854–862.
15.
Mattano, Leonard A., Meenakshi Devidas, Alison M. Friedmann, et al.. (2014). Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331. Blood. 124(21). 793–793.
16.
Hijiya, Nobuko, Blythe Thomson, Michael S. Isakoff, et al.. (2011). Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 118(23). 6043–6049.
17.
Gutiérrez, Alejandro, Suzanne E. Dahlberg, Donna Neuberg, et al.. (2010). Absence of Biallelic TCR γ Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 28(24). 3816–3823.
18.
Schultz, Kirk R., W. Paul Bowman, Alexander Aledo, et al.. (2009). Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology. 27(31). 5175–5181.
19.
Johnson, David A., et al.. (1989). Monoclonal Antibody L/1C2 Reactive with a Human Carcinoma Associated Antigen. Hybridoma. 8(2). 161–173.
20.
Bumol, Thomas F., et al.. (1988). Characterization of the Human Tumor and Normal Tissue Reactivity of the KS1/4 Monoclonal Antibody. Hybridoma. 7(4). 407–415.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mark R. Litzow Breakdown of academic impact, for papers by Ravi Bhatia Breakdown of academic impact, for papers by Hillard M. Lazarus Breakdown of academic impact, for papers by Elias Jabbour Breakdown of academic impact, for papers by Dietger Niederwieser Breakdown of academic impact, for papers by Farhad Ravandi Breakdown of academic impact, for papers by Aloïs Gratwohl Breakdown of academic impact, for papers by James W. Vardiman Breakdown of academic impact, for papers by Mary M. Horowitz Breakdown of academic impact, for papers by Charles A. Schiffer